



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov



Bib Data Sheet

CONFIRMATION NO. 2590

<b>SERIAL NUMBER</b> 10/827,294	<b>FILING OR 371(c) DATE</b> 04/20/2004 <b>RULE</b>	<b>CLASS</b> 544	<b>GROUP ART UNIT</b> 1624	<b>ATTORNEY DOCKET NO.</b> 0283-0192PUS1
------------------------------------	---	---------------------	-------------------------------	---

## APPLICANTS

Akira Kubo, Osaka, JAPAN;  
Ritsuo Imashiro, Osaka, JAPAN;  
Hiroaki Sakurai, Toyama-shi, JAPAN;  
Hidetaka Miyoshi, Osaka, JAPAN;  
Akihito Ogasawara, Toda-shi, JAPAN;  
Hajime Hiramatsu, Osaka, JAPAN;  
Tatsuo Nakajima, Osaka, JAPAN;  
Tetsu Nakane, Amagasaki-shi, JAPAN;.

## \*\* CONTINUING DATA \*\*\*\*\*

*OK* This application is a CIP of PCT/JP02/10937 10/22/2002

## \*\* FOREIGN APPLICATIONS \*\*\*\*\*

JAPAN 2001-324029 10/22/2001  
JAPAN 2002-263680 09/10/2002  
JAPAN 2003-116076 04/21/2003

*OK*  
IF REQUIRED, FOREIGN FILING LICENSE GRANTED \*\*  
06/28/2004

Foreign Priority claimed <input checked="" type="checkbox"/> yes <input type="checkbox"/> no	<b>STATE OR COUNTRY</b> JAPAN	<b>SHEETS DRAWING</b> 0	<b>TOTAL CLAIMS</b> 19	<b>INDEPENDENT CLAIMS</b> 3
35 USC 119 (a-d) conditions met <input checked="" type="checkbox"/> yes <input type="checkbox"/> no <input type="checkbox"/> Met after Allowance				
Verified and Acknowledged <i>[Signature]</i> Examiner's Signature	<i>OK</i> Initials			

## ADDRESS

2292

## TITLE

4-Imidazolin-2-one compounds

<b>FILING FEE RECEIVED</b> 2050	FEES: Authority has been given in Paper No. _____ to charge/credit DEPOSIT ACCOUNT No. _____ for following:	<input type="checkbox"/> All Fees <input type="checkbox"/> 1.16 Fees ( Filing ) <input type="checkbox"/> 1.17 Fees ( Processing Ext. of time ) <input type="checkbox"/> 1.18 Fees ( Issue ) <input type="checkbox"/> Other _____ <input type="checkbox"/> Credit
--	---	---